FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152608034> ?p ?o ?g. }

• W2152608034 abstract "Multiple sclerosis (MS) is the most common inflammatory demyelinating disorder of the central nervous system (CNS). Minocycline ameliorates the clinical severity of MS and exhibits antiinflammatory, neuroprotective activities, and good tolerance for long-term use, whereas it is toxic to the CNS. Recently, the immunomodulation and neuroprotection capabilities of human bone marrow mesenchymal stem cells (hBM-MSCs) were shown in experimental autoimmune encephalomyelitis (EAE). In this study, we evaluated whether the combination of hBM-MSCs and a low-dose minocycline could produce beneficial effects in EAE mice. The sensitivity of hBM-MSCs to minocycline was determined by an established cell-viability assay. Minocycline-treated hBM-MSCs were also characterized with flow cytometry by using MSC surface markers and analyzed for their multiple differentiation capacities. EAE was induced in C57BL/6 mice by using immunization with MOG35-55. Immunopathology assays were used to detect the inflammatory cells, demyelination, and neuroprotection. Interferon gamma (IFN-γ)/tumor necrosis factor alpha (TNF-α) and interleukin-4 (IL-4)/interleukin-10 (IL-10), the hallmark cytokines that direct Th1 and Th2 development, were detected with enzyme-linked immunosorbent assay (ELISA). terminal dUTP nick-end labeling (TUNEL) staining was performed to elucidate the cell apoptosis in the spinal cords of EAE mice. Minocycline did not affect the viability, surface phenotypes, or differentiation capacity of hBM-MSCs, while minocycline affected the viability of astrocytes at a high dose. In vivo efficacy experiments showed that combined treatment, compared to the use of minocycline or hBM-MSCs alone, resulted in a significant reduction in clinical scores, along with attenuation of inflammation, demyelination, and neurodegeneration. Moreover, the combined treatment with hBM-MSCs and minocycline enhanced the immunomodulatory effects, which suppressed proinflammatory cytokines (IFN-γ, TNF-α) and conversely increased anti-inflammatory cytokines (IL-4, IL-10). In addition, TUNEL staining also demonstrated a significant decrease of the number of apoptotic cells in the combined treatment compared with either treatment alone. The combination of hBM-MSCs and minocycline provides a novel experimental protocol to enhance the therapeutic effects in MS." @default.
• W2152608034 created "2016-06-24" @default.
• W2152608034 creator A5006055109 @default.
• W2152608034 creator A5025616053 @default.
• W2152608034 creator A5031694233 @default.
• W2152608034 creator A5040221900 @default.
• W2152608034 creator A5047995089 @default.
• W2152608034 creator A5073951681 @default.
• W2152608034 date "2013-07-05" @default.
• W2152608034 modified "2023-10-11" @default.
• W2152608034 title "Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice" @default.
• W2152608034 cites W1924525408 @default.
• W2152608034 cites W1942668068 @default.
• W2152608034 cites W1970538025 @default.
• W2152608034 cites W1970621111 @default.
• W2152608034 cites W1973681520 @default.
• W2152608034 cites W1983909073 @default.
• W2152608034 cites W1989692987 @default.
• W2152608034 cites W1990410752 @default.
• W2152608034 cites W1994437674 @default.
• W2152608034 cites W1996932153 @default.
• W2152608034 cites W1997482574 @default.
• W2152608034 cites W1998538509 @default.
• W2152608034 cites W2001118602 @default.
• W2152608034 cites W2009001438 @default.
• W2152608034 cites W2010453211 @default.
• W2152608034 cites W2025732446 @default.
• W2152608034 cites W2030412297 @default.
• W2152608034 cites W2035976926 @default.
• W2152608034 cites W2046808668 @default.
• W2152608034 cites W2057721119 @default.
• W2152608034 cites W2063885093 @default.
• W2152608034 cites W2079482093 @default.
• W2152608034 cites W2085429548 @default.
• W2152608034 cites W2088190804 @default.
• W2152608034 cites W2091526175 @default.
• W2152608034 cites W2106117542 @default.
• W2152608034 cites W2106647511 @default.
• W2152608034 cites W2113617025 @default.
• W2152608034 cites W2116608035 @default.
• W2152608034 cites W2145557612 @default.
• W2152608034 cites W2154677662 @default.
• W2152608034 cites W2158230836 @default.
• W2152608034 cites W2159358845 @default.
• W2152608034 cites W2159999899 @default.
• W2152608034 cites W2169021826 @default.
• W2152608034 cites W2171769546 @default.
• W2152608034 cites W2286903127 @default.
• W2152608034 cites W2332018470 @default.
• W2152608034 cites W4238498163 @default.
• W2152608034 doi "https://doi.org/10.1186/scrt228" @default.
• W2152608034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3854709" @default.
• W2152608034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23826999" @default.
• W2152608034 hasPublicationYear "2013" @default.
• W2152608034 type Work @default.
• W2152608034 sameAs 2152608034 @default.
• W2152608034 citedByCount "35" @default.
• W2152608034 countsByYear W21526080342013 @default.
• W2152608034 countsByYear W21526080342014 @default.
• W2152608034 countsByYear W21526080342015 @default.
• W2152608034 countsByYear W21526080342016 @default.
• W2152608034 countsByYear W21526080342017 @default.
• W2152608034 countsByYear W21526080342018 @default.
• W2152608034 countsByYear W21526080342020 @default.
• W2152608034 countsByYear W21526080342021 @default.
• W2152608034 countsByYear W21526080342022 @default.
• W2152608034 countsByYear W21526080342023 @default.
• W2152608034 crossrefType "journal-article" @default.
• W2152608034 hasAuthorship W2152608034A5006055109 @default.
• W2152608034 hasAuthorship W2152608034A5025616053 @default.
• W2152608034 hasAuthorship W2152608034A5031694233 @default.
• W2152608034 hasAuthorship W2152608034A5040221900 @default.
• W2152608034 hasAuthorship W2152608034A5047995089 @default.
• W2152608034 hasAuthorship W2152608034A5073951681 @default.
• W2152608034 hasBestOaLocation W21526080341 @default.
• W2152608034 hasConcept C142724271 @default.
• W2152608034 hasConcept C17991360 @default.
• W2152608034 hasConcept C198826908 @default.
• W2152608034 hasConcept C203014093 @default.
• W2152608034 hasConcept C25498285 @default.
• W2152608034 hasConcept C2777899865 @default.
• W2152608034 hasConcept C2778275353 @default.
• W2152608034 hasConcept C2778486448 @default.
• W2152608034 hasConcept C2780007613 @default.
• W2152608034 hasConcept C2780640218 @default.
• W2152608034 hasConcept C28328180 @default.
• W2152608034 hasConcept C501593827 @default.
• W2152608034 hasConcept C71924100 @default.
• W2152608034 hasConcept C86803240 @default.
• W2152608034 hasConcept C89423630 @default.
• W2152608034 hasConcept C95444343 @default.
• W2152608034 hasConcept C98274493 @default.
• W2152608034 hasConceptScore W2152608034C142724271 @default.
• W2152608034 hasConceptScore W2152608034C17991360 @default.
• W2152608034 hasConceptScore W2152608034C198826908 @default.
• W2152608034 hasConceptScore W2152608034C203014093 @default.
• W2152608034 hasConceptScore W2152608034C25498285 @default.
• W2152608034 hasConceptScore W2152608034C2777899865 @default.
• W2152608034 hasConceptScore W2152608034C2778275353 @default.
• W2152608034 hasConceptScore W2152608034C2778486448 @default.

• next